Is a skin test needed before administering tetanus toxoid (TT) and Tetanus immunoglobulin (TIG) to a patient with an unknown vaccination history and a potentially contaminated wound?

Skin Testing Is Not Needed Before Administering Tetanus Toxoid or Tetanus Immunoglobulin

Skin tests should not be performed before administering tetanus toxoid (TT) or tetanus immunoglobulin (TIG), as the FDA explicitly states that intradermal injection of concentrated IgG solutions causes localized inflammation that can be misinterpreted as a positive allergic reaction, leading physicians to inappropriately withhold needed treatment. 1

Why Skin Testing Is Contraindicated

• The FDA drug label for TIG clearly states: "Skin tests should not be done" because the intradermal injection creates localized tissue irritation that does not represent true allergy but rather local inflammation. 1

• Misinterpretation of these false-positive results can lead to dangerous withholding of necessary passive immunization from patients who are not actually allergic to the material. 1

• True allergic responses to human immunoglobulin given intramuscularly are rare, making routine skin testing both unnecessary and potentially misleading. 1

Proper Administration Without Skin Testing

For Patients with Unknown or Incomplete Vaccination History (<3 doses)

• The CDC recommends administering BOTH tetanus toxoid-containing vaccine (Tdap preferred) AND TIG 250 units IM at separate anatomical sites using separate syringes for patients with tetanus-prone wounds and unknown or incomplete vaccination history. 2, 3, 1

• No skin testing is required before either injection—proceed directly to administration after confirming the indication. 1

• Tetanus-prone wounds include those contaminated with dirt, feces, soil, saliva, puncture wounds, avulsions, and wounds from missiles, crushing, burns, or frostbite. 3, 1

For Patients with Complete Vaccination History (≥3 doses)

• For clean, minor wounds: administer tetanus toxoid only if ≥10 years since last dose; no TIG needed regardless of interval. 2, 1

• For contaminated/tetanus-prone wounds: administer tetanus toxoid if ≥5 years since last dose; no TIG needed. 2, 1

• Again, no skin testing is performed in any scenario. 1

Safety Precautions That Actually Matter

What to Have Available

• Although systemic reactions to human immunoglobulin preparations are rare, epinephrine should be available for treatment of acute anaphylactic reactions. 1

• This is standard emergency preparedness, not an indication for pre-administration skin testing. 1

Proper Injection Technique

• TIG must be given intramuscularly only—never intravenously—as IV injection can cause precipitous blood pressure drops resembling anaphylaxis. 1

• Draw back on the syringe plunger before injection to ensure the needle is not in a blood vessel. 1

• Administer preferably in the deltoid muscle of the upper arm or lateral thigh muscle; avoid the gluteal region due to risk of sciatic nerve injury. 1

• When giving both TIG and tetanus toxoid, use separate syringes at different anatomical sites to prevent interference with immune response. 2, 3, 1

Clinical Context: Why This Question Arises

• The confusion about skin testing likely stems from historical practices with equine (horse serum) antitoxin, which required sensitivity testing due to high rates of serum sickness. 3

• Modern human TIG does not require such testing because it is derived from human plasma and has dramatically lower allergic potential. 3

• Research confirms that true IgE-mediated reactions to tetanus toxoid are extremely rare (incidence 0.001%), and when they occur, they can be diagnosed through clinical history and specific IgE testing—not through pre-administration skin testing. 4

Critical Pitfall to Avoid

• Do not delay or withhold tetanus prophylaxis to perform skin testing. The FDA explicitly warns against this practice, and case reports demonstrate that failure to administer appropriate prophylaxis can result in preventable tetanus cases, even in patients with prior vaccination. 1, 5

• A 2024 case report documented generalized tetanus in a 79-year-old woman with confirmed immunization whose last booster was seven years prior—she should have received tetanus toxoid for her high-risk wound but did not, resulting in severe disease requiring prolonged intensive care. 5